Product Images Doxazosin
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Doxazosin NDC 51655-130 by Northwind Pharmaceuticals, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - 51655 130 52 Rev A 02 23
This is a description of a medication with a National Drug Code (NDC) of 51655-130-52. The medication is Doxazosin and comes in a tablet form with a strength of 4 mg. The package contains 30 tablets and is only available with a prescription. The recommended dosage can be found in the package insert. The medication should be stored at a temperature between 25°C-30°C (77°F-86°F) and kept out of reach of children. The tablets are made by Upsher-Smith Laboratories, LLC and have been repackaged by Northwind Pharmaceuticals with a GTIN of 00351655130520. The lot number for this medication is 0000000000 and the serial number is 000000000000000. The expiration date is 00/00/0000.*
Chemical Structure - doxazosin 01
Table 3 - doxazosin 02
The text presents several studies related to the maximum flow rate and symptom score of patients with BPH who received different dosages of doxazosin or placebo. The studies were conducted with a modified Boyarsky questionnaire and AUA questionnaire. The results showed that the maximum flow rate increased and the symptom score decreased in patients who received doxazosin compared to those who received a placebo. There were statistically significant differences in some of the mean changes.*
Figure 1 - doxazosin 03
The text provides a figure (Study 1) that shows the mean change in total symptom score and the mean increase in maximum urinary flow rate from baseline in 47 people after treatment with Doxazosin for varying durations (week 0 to week 14). The figure suggests a statistically significant improvement in both the symptom score and urinary flow rate compared to placebo, with the maximum improvement observed after eight weeks of treatment.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.